Literature DB >> 23492193

Size-dependent uptake of particles by pulmonary antigen-presenting cell populations and trafficking to regional lymph nodes.

Fabian Blank1, Philip A Stumbles, Emilie Seydoux, Patrick G Holt, Alke Fink, Barbara Rothen-Rutishauser, Deborah H Strickland, Christophe von Garnier.   

Abstract

The respiratory tract is an attractive target organ for novel diagnostic and therapeutic applications with nano-sized carriers, but their immune effects and interactions with key resident antigen-presenting cells (APCs) such as dendritic cells (DCs) and alveolar macrophages (AMs) in different anatomical compartments remain poorly understood. Polystyrene particles ranging from 20 nm to 1,000 nm were instilled intranasally in BALB/c mice, and their interactions with APC populations in airways, lung parenchyma, and lung-draining lymph nodes (LDLNs) were examined after 2 and 24 hours by flow cytometry and confocal microscopy. In the main conducting airways and lung parenchyma, DC subpopulations preferentially captured 20-nm particles, compared with 1,000-nm particles that were transported to the LDLNs by migratory CD11blow DCs and that were observed in close proximity to CD3⁺ T cells. Generally, the uptake of particles increased the expression of CD40 and CD86 in all DC populations, independent of particle size, whereas 20-nm particles induced enhanced antigen presentation to CD4⁺ T cells in LDLNs in vivo. Despite measurable uptake by DCs, the majority of particles were taken up by AMs, irrespective of size. Confocal microscopy and FACS analysis showed few particles in the main conducting airways, but a homogeneous distribution of all particle sizes was evident in the lung parenchyma, mostly confined to AMs. Particulate size as a key parameter determining uptake and trafficking therefore determines the fate of inhaled particulates, and this may have important consequences in the development of novel carriers for pulmonary diagnostic or therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23492193     DOI: 10.1165/rcmb.2012-0387OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  34 in total

1.  A Jagged 1-Notch 4 molecular switch mediates airway inflammation induced by ultrafine particles.

Authors:  Mingcan Xia; Hani Harb; Arian Saffari; Constantinos Sioutas; Talal A Chatila
Journal:  J Allergy Clin Immunol       Date:  2018-04-05       Impact factor: 10.793

2.  Encapsulation of an EP67-Conjugated CTL Peptide Vaccine in Nanoscale Biodegradable Particles Increases the Efficacy of Respiratory Immunization and Affects the Magnitude and Memory Subsets of Vaccine-Generated Mucosal and Systemic CD8+ T Cells in a Diameter-Dependent Manner.

Authors:  Bala V K Karuturi; Shailendra B Tallapaka; Pravin Yeapuri; Stephen M Curran; Sam D Sanderson; Joseph A Vetro
Journal:  Mol Pharm       Date:  2017-04-03       Impact factor: 4.939

3.  Comparison of the interleukin-1β-inducing potency of allergenic spores from higher fungi (basidiomycetes) in a cryopreserved human whole blood system.

Authors:  Félix E Rivera-Mariani; Kranthi Vysyaraju; Jesse Negherbon; Estelle Levetin; W Elliot Horner; Thomas Hartung; Patrick N Breysse
Journal:  Int Arch Allergy Immunol       Date:  2013-12-17       Impact factor: 2.749

4.  Pulmonary biodistribution and cellular uptake of intranasally administered monodisperse particles.

Authors:  Timothy M Brenza; Latrisha K Petersen; Yanjie Zhang; Lucas M Huntimer; Amanda E Ramer-Tait; Jesse M Hostetter; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Pharm Res       Date:  2014-10-09       Impact factor: 4.200

5.  Biodegradable Viral Nanoparticle/Polymer Implants Prepared via Melt-Processing.

Authors:  Parker W Lee; Sourabh Shukla; Jaqueline D Wallat; Chaitanya Danda; Nicole F Steinmetz; Joao Maia; Jonathan K Pokorski
Journal:  ACS Nano       Date:  2017-09-13       Impact factor: 15.881

Review 6.  A work group report on ultrafine particles (American Academy of Allergy, Asthma & Immunology): Why ambient ultrafine and engineered nanoparticles should receive special attention for possible adverse health outcomes in human subjects.

Authors:  Ning Li; Steve Georas; Neil Alexis; Patricia Fritz; Tian Xia; Marc A Williams; Elliott Horner; Andre Nel
Journal:  J Allergy Clin Immunol       Date:  2016-04-06       Impact factor: 10.793

Review 7.  Epithelial barrier function: at the front line of asthma immunology and allergic airway inflammation.

Authors:  Steve N Georas; Fariba Rezaee
Journal:  J Allergy Clin Immunol       Date:  2014-07-29       Impact factor: 10.793

8.  Evaluating UiO-66 Metal-Organic Framework Nanoparticles as Acid-Sensitive Carriers for Pulmonary Drug Delivery Applications.

Authors:  Bader M Jarai; Zachary Stillman; Lucas Attia; Gerald E Decker; Eric D Bloch; Catherine A Fromen
Journal:  ACS Appl Mater Interfaces       Date:  2020-08-20       Impact factor: 9.229

9.  Environmental exposures and innate immunity in the lung.

Authors:  Steve N Georas; John Upham
Journal:  J Environ Immunol Toxicol       Date:  2014-01

Review 10.  Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases.

Authors:  Caleb F Anderson; Maria E Grimmett; Christopher J Domalewski; Honggang Cui
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.